| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Over the past 90 days, insiders at Nurix Therapeutics, Inc. (NRIX) have been net sellers, shedding 49,260 shares worth roughly $1.2M on balance. In the past 30 days, 0 insiders bought and 4 sold.
All 4 insiders who sold still hold shares after their sales.
Counted by filing, the last 12 months brought no open-market purchases and 34 sales by 4 insiders worth about $5.3M. The 12 months before that brought no open-market purchases and 20 sales by 3 insiders worth about $1.3M.
22 of the 34 sales in the last 12 months were made under a Rule 10b5-1 trading plan; the rest were not.
No open-market purchase by an insider appears in the NRIX Form 4 filings on record.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 123.5K | $3.19M | -6,861 | |
| CFO | 47.5K | $1.23M | -2,834 | |
| Other | 15.3K | $395.9K | -3,957 | |
| Dir | 10.8K | $277.6K | -22,583 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Gwenn Hansen70 | Chief Scientific Officer | Sale+OE10b5-1 | 5,409 | $26.42 | $142,900.00 | -4.2% | - | - | |
| Oct 30, 2026 | Hans van Houte56 | Chief Financial Officer | Sale+OE | 2,834 | $26.28 | $74,474.97 | -5.6% | - | - | |
| Oct 30, 2026 | Christine Ring75 | Chief Legal Officer | Sale+OE | 3,957 | $26.28 | $103,986.40 | -20.5% | - | - | |
| Oct 15, 2026 | Gwenn Hansen70 | Chief Scientific Officer | Sale+OE10b5-1 | 1,452 | $25.00 | $36,300.00 | -1.2% | - | - | |
| Oct 14, 2026 | Julia P Gregory | Director | Sale+OE | 22,583 | $23.40 | $528,528.02 | -67.7% | - | - | |
| Oct 2, 2026 | Christine Ring75 | Chief Legal Officer | Sale+OE10b5-1 | 5,786 | $23.19 | $134,148.99 | -38.8% | - | - | |
| Sep 2, 2026 | Christine Ring75 | Chief Legal Officer | Sale+OE10b5-1 | 5,787 | $25.76 | $149,072.35 | -38.8% | - | - | |
| Sep 1, 2026 | Gwenn Hansen70 | Chief Scientific Officer | Sale+OE10b5-1 | 1,452 | $25.47 | $36,982.44 | -1.2% | - | - | |
| Aug 5, 2026 | Gwenn Hansen70 | Chief Scientific Officer | Sale+OE10b5-1 | 4,356 | $25.00 | $108,900.00 | -3.6% | +8.0% | - | |
| Aug 4, 2026 | Hans van Houte56 | Chief Financial Officer | Sell10b5-1 | 4,761 | $24.36 | $115,989.47 | -10.6% | +9.8% | - |